<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="causing cell damage. Based on prior in-vitro studies on SARS-CoV," exact="amiodarone" post="and other cationic amphiphilic drugs like dronedarone, verapamil, and"/>
 <result pre="Many of the â€œoff-labelâ€� COVID-19 therapies including (hydroxy)chloroquine, lopinavir/ritonavir and" exact="azithromycin" post="have either known or possible risk of TdP due"/>
 <result pre="due to their effect on QT prolongation (59). (Hydroxy)chloroquine and" exact="azithromycin" post="inhibit the hERG-K+ channel, which causes prolongation of action"/>
 <result pre="cohort study of 90 hospitalized COVID-19 patients, the administration of" exact="hydroxychloroquine" post="with or without azithromycin was associated with an increased"/>
 <result pre="hospitalized COVID-19 patients, the administration of hydroxychloroquine with or without" exact="azithromycin" post="was associated with an increased risk of QTc prolongation"/>
 <result pre="drugs, or myocardial ischemia. In patients with supraventricular tachycardia, intravenous" exact="adenosine" post="can be used for acute termination, although further validation"/>
 <result pre="are hemodynamically stable, consider discontinuing antiarrhythmic drugs (AADs) especially sotalol," exact="flecainide" post="and likely amiodarone and propafenone given serious drug-drug interactions"/>
 <result pre="consider discontinuing antiarrhythmic drugs (AADs) especially sotalol, flecainide and likely" exact="amiodarone" post="and propafenone given serious drug-drug interactions with antiviral drugs"/>
 <result pre="antiarrhythmic drugs (AADs) especially sotalol, flecainide and likely amiodarone and" exact="propafenone" post="given serious drug-drug interactions with antiviral drugs and to"/>
 <result pre="close monitoring with caution is recommended with the use of" exact="amiodarone" post="in patients undergoing treatment with fingolimod. Propafenone or flecainide"/>
 <result pre="the use of amiodarone in patients undergoing treatment with fingolimod." exact="Propafenone" post="or flecainide is preferred in structurally normal hearts who"/>
 <result pre="of amiodarone in patients undergoing treatment with fingolimod. Propafenone or" exact="flecainide" post="is preferred in structurally normal hearts who are on"/>
 <result pre="flecainide is preferred in structurally normal hearts who are on" exact="fingolimod" post="(63). Transthoracic echocardiography (TTE) is recommended only in hemodynamically"/>
 <result pre="the previously mentioned causes, the first choice of therapy is" exact="amiodarone" post="or intravenous lidocaine, especially if underlying myocardial infarction is"/>
 <result pre="recommended that all patients with COVID-19 self-medicate with paracetamol or" exact="acetaminophen" post="if they develop fever. High-risk BrS patients who develop"/>
 <result pre="administered with great caution in critically ill patients. BBs and" exact="flecainide" post="should be continued while monitoring interactions with antiviral drugs."/>
 <result pre="days) versus high-dose (600Â mg twice daily for 10Â days)" exact="chloroquine" post="in addition to azithromycin in severe COVID-19 patients showed"/>
 <result pre="mg twice daily for 10Â days) chloroquine in addition to" exact="azithromycin" post="in severe COVID-19 patients showed lethality in the higher"/>
 <result pre="to 10.6) and thus recommended against the use of high-dose" exact="chloroquine" post="in severe cases (68). Traditionally, the Tisdale risk score,"/>
 <result pre="Clinic for patients in whom QTc-prolonging drugs like (hydroxy)chloroquine Â±" exact="azithromycin" post="or lopinavir/ritonavirÂ are under consideration recommend to obtain a"/>
 <result pre="â‰¥60Â ms, 2 to 3Â h after a dose of" exact="hydroxychloroquine" post="or other QT-prolonging agent, we recommend re-evaluation of the"/>
 <result pre="etÂ al. (72) reports a possible benefit of addition of" exact="lidocaine" post="or mexiletine to allow combination therapy with azithromycin and"/>
 <result pre="addition of lidocaine or mexiletine to allow combination therapy with" exact="azithromycin" post="and chloroquine in patients with a prolonged QT interval."/>
 <result pre="lidocaine or mexiletine to allow combination therapy with azithromycin and" exact="chloroquine" post="in patients with a prolonged QT interval. Class Ib"/>
 <result pre="amiodarone, propafenone, flecainide, quinidine, and some novel oral anticoagulants including" exact="apixaban" post="and rivaroxaban, which are metabolized mainly by different CP450"/>
 <result pre="for COVID-19 Therapy With Cardiac Drugs Treatment Select Drug-Drug Interactionsâˆ—" exact="Azithromycin" post="â†&quot; in HR, â†‘ PR interval, â†‘â†‘ in QTc"/>
 <result pre="of TdP.AAD drug interactions: Severe: amiodarone, disopyramide, dofetilide, flecainide, sotalol," exact="propafenone" post="Moderate: BBs, digoxin (Hydroxy) chloroquine â†&quot; in HR, â†‘"/>
 <result pre="interactions: Severe: amiodarone, disopyramide, dofetilide, flecainide, sotalol, propafenone Moderate: BBs," exact="digoxin" post="(Hydroxy) chloroquine â†&quot; in HR, â†‘ PR interval, â†‘â†‘"/>
 <result pre="amiodarone, disopyramide, dofetilide, flecainide, sotalol, propafenone Moderate: BBs, digoxin (Hydroxy)" exact="chloroquine" post="â†&quot; in HR, â†‘ PR interval, â†‘â†‘ in QTc"/>
 <result pre="risk of TdP.AAD drug interactions: Severe: amiodarone, flecainide, mexiletine, sotalol," exact="dofetilide" post="Moderate: disopyramide, propafenone, quinidine, digoxin Mild: metoprolol, nebivolol, propranolol,"/>
 <result pre="Severe: amiodarone, flecainide, mexiletine, sotalol, dofetilide Moderate: disopyramide, propafenone, quinidine," exact="digoxin" post="Mild: metoprolol, nebivolol, propranolol, timolol, verapamil Lopinavir/ritonavir â†‘ PR"/>
 <result pre="Moderate: disopyramide, propafenone, quinidine, digoxin Mild: metoprolol, nebivolol, propranolol, timolol," exact="verapamil" post="Lopinavir/ritonavir â†‘ PR interval, â†‘â†‘ in QTc interval with"/>
 <result pre="risk of TdP.AAD interactions: Moderate: BBs, CCBs, ivabradine, amiodarone, flecainide," exact="propafenone" post="Ribavirin Unknown Tocilizumab No ECG changes describedAAD interactions: Mild:"/>
 <result pre="of TdP.AAD interactions: Moderate: BBs, CCBs, ivabradine, amiodarone, flecainide, propafenone" exact="Ribavirin" post="Unknown Tocilizumab No ECG changes describedAAD interactions: Mild: amiodarone,"/>
 <result pre="Unknown Tocilizumab No ECG changes describedAAD interactions: Mild: amiodarone, quinidine" exact="Methylprednisolone" post="Unknown Interferon alfa-1 Unknown â†‘/â†&quot;Â =Â mild increase/decrease; â†‘â†‘/â†&quot;â†&quot;Â"/>
 <result pre="Proc9520201213122132359771 60MercuroN.J.YenC.F.ShimD.J.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
 <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
 <result pre="arrhythmia syndromesHeart Rhythm2020 Mar 31[E-pub ahead of print] 67RamireddyA.ChughH.S.ReinierK.Experience with" exact="hydroxychloroquine" post="and azithromycin in the COVID-19 pandemic: implications for QT"/>
 <result pre="Rhythm2020 Mar 31[E-pub ahead of print] 67RamireddyA.ChughH.S.ReinierK.Experience with hydroxychloroquine and" exact="azithromycin" post="in the COVID-19 pandemic: implications for QT interval monitoringJÂ"/>
 <result pre="Am Heart Assoc92020e017144 68BorbaM.G.S.ValF.F.A.SampaioV.S.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="prolongation in coronavirus disease 2019 (COVID-19) patients treated with either" exact="chloroquine" post="or hydroxychloroquine in conjunction with azithromycin: Possible benefits of"/>
 <result pre="coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or" exact="hydroxychloroquine" post="in conjunction with azithromycin: Possible benefits of intravenous lidocaineHeartRhythm"/>
</results>
